NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02099747,hATG+CsA vs hATG+CsA+Eltrombopag for SAA,https://clinicaltrials.gov/study/NCT02099747,RACE,COMPLETED,The null hypothesis of no difference in CR% at 3 months between the arms will be tested against the alternative of a difference in CR% at an alpha level of .05 by assessing the odds ratio for arm yielded by this model.,NO,Severe Aplastic Anemia,DRUG: hATG|DRUG: CsA|DRUG: Eltrombopag,"CR rate, The primary objective of this trial is to investigate whether Eltrombopag added to standard immunosuppressive treatment increases the rate of early (at three months) complete response in untreated AA patient., 3 months","Time to best heamatological response, 2 year|Heamatological Response at 6, 12, 18 and 24 months, 2 year|Cumulative incidence of response, 2 year|Overall survival, 2 year|Event-free survival, 2 year|Cumulative incidence of relapse rate, 2 year|Cumulative incidences of clonal evolution, 2 year|Cumulative incidence of PNH population occurrence and clinical hemolytic PNH occurrence, 2 year|Cumulative incidence of discontinuation of immunosuppressive therapy, 2 year|Rate of CsA-independent hematological response at 24 months, 2 year|Need for transfusions and number of transfusions required from treatment, 2 year|Need for any supportive care, 2 year|Comparison of number of SAEs between the two arms, To look for the safety and tolerability of the investigational treatment, 2 year",,European Society for Blood and Marrow Transplantation,Novartis|Pfizer,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,202,NETWORK,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,EBMT-RACE|2014-000363-40,2015-07,2020-12,2020-12,2014-03-31,,2020-12-22,"Hopital Jean Minjoz, Besancon, France|Hôpital Haut-Lévèque, Bordeaux, France|Hôpital Huriez, Lille, France|Centre Hospitalier Lyon-Sud, Lyon, France|St. Louis Hospital, Paris, France|Pontchaillou Hospital, Rennes, France|Hôpital Purpan, Toulouse, France|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Istituto G. Gaslini children's Hospital, Genova, Italy|San Martino Hospital, Genova, Italy|Fondazione IRCCS ca Granda Ospedale, Milan, Italy|'Federico II' Medical School, Naples, Italy|La Sapienza University Hospital, Rome, Italy|AOU Città della Salute e della Scienza di Torino, Turin, Italy|AMC, Amsterdam, Netherlands|UMCG, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|UMCU, Utrecht, Netherlands|Hospital Universitari Germans Trias I Pujol, Badalona, Spain|Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain|Donostia Hospital, San Sebastian, Spain|Hospital La Fe, Valencia, Spain|University Hospital Basel, Basel, Switzerland|University Hospital Bern, Bern, Switzerland|University Hospital Zürich, Zürich, Switzerland|St. James Hospital, Leeds, United Kingdom|King's College Hospital, London, United Kingdom|St. Bartholomew's Hospital, London, United Kingdom|City Hospital, Nottingham, United Kingdom",
